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A B S T R A C T
Carnitine acetyltransferase (CRAT) deﬁciency has previously been shown to result in muscle insulin resistance
due to accumulation of long-chain acylcarnitines. However, diﬀerences in the acylcarnitine proﬁle and/or
changes in gene expression and protein abundance of CRAT in myotubes obtained from obese patients with type
2 diabetes mellitus (T2DM) and glucose-tolerant obese and lean controls remain unclear. The objective of the
study was to examine whether myotubes from obese patients with T2DM express diﬀerences in gene expression
and protein abundance of CRAT and in acylcarnitine species pre-cultured under glucose and insulin
concentrations similar to those observed in healthy individuals in the over-night fasted, resting state.
Primary myotubes obtained from obese persons with or without T2DM and lean controls (n=9 in each group)
were cultivated and harvested for LC-MS-based proﬁling of acylcarnitines. The mRNA expression and protein
abundance of CRAT were determined by qPCR and Western Blotting, respectively. Our results suggest that the
mRNA levels and protein abundance of CRAT were similar between groups. Of the 14 diﬀerent acylcarnitine
species measured by LC-MS, the levels of palmitoylcarnitine (C16) and octadecanoylcarnitine (C18) were
slightly reduced in myotubes derived from T2DM patients (p < 0.05) compared to glucose-tolerant obese and
lean controls. This suggests that the CRAT function is not the major contributor to primary insulin resistance in
cultured myotubes obtained from obese T2DM patients.
1. Introduction
Carnitine acetyltransferase (CRAT), a mitochondrial matrix enzyme
proposed as a potent regulator of metabolic inﬂexibility, has been
found to impact whole-body glucose homeostasis and muscle-speciﬁc
loss of function results in reduced metabolic control, which resembles
the insulin resistant state [1]. A study conducted by Noland and
colleagues suggests that CRAT overexpression in primary human
skeletal myocytes increased glucose uptake and improved lipid-induced
suppression of glucose oxidation [2]. In this regard, CRAT could be
involved in the compensatory response to glucose intolerance.
However, the potential role of CRAT within skeletal muscle insulin
resistance is poorly understood.
Recently, Seiler and colleagues proposed that CRAT activity was
decreased in response to genetic diabetes, high-fat diet and lipid
exposure [3]. They also stated that reduced CRAT activity was
accompanied by accumulation of long chain acylcarnitines in skeletal
muscle and a decline in the acetylcarnitine/acetyl coenzyme A (CoA)
ratio [3]. Since long chain acylcarnitines have been shown to be
associated with insulin resistance, and reﬂect increased lipid ﬂux in
T2DM [4], it is possible that carnitine supplementation is an ideal
solution for treating T2DM [1]. However, contradictory results have
shown that muscular lipid oxidation is normal or even increased in
T2DM patients and mice fed a high-fat diet [5].
Previously, we have shown that myotubes established from T2DM
patients express primary insulin resistance at the level of glucose
uptake, storage and oxidation [6], however, the molecular background
is unclear. In the present study, we took advance of this model to
investigate CRAT expression and acylcarnitine distribution under basal
conditions, in order to clarify whether changes in mRNA levels and
protein abundance of CRAT and/or the present acylcarnitine proﬁle
can explain primary (genetic) insulin resistance in these cells.
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2. Methods
2.1. Participants and cell culture
The present study examined myotubes obtained and cultured from
muscle biopsies collected in a previously reported study [7]. In brief, 10
obese T2DM patients were matched to 10 obese and 10 lean control
participants according to BMI, age and gender. Their clinical char-
acteristics have previously been published [7] (Table 1). All partici-
pants gave written, informed consent, and the local ethics committee of
Funen and Vejle County approved the study. Human myotubes cultures
were established as previously described [6–8] and allowed to diﬀer-
entiate under basal conditions of insulin (25 pmol/l) and glucose
(5.5 mmol/l) for 8 days, similar to those observed in healthy indivi-
duals in the over-night fasted, resting state. However, one person in
each group was lost under sample preparation. Therefore, only nine
persons in each group were used.
2.2. Metabolic proﬁling of acylcarnitines
The human myotubes were harvested in cold PBS and sonicated for
10–15 min. Protein concentrations were determined using the Pierce
BCA protein assay kit. Internal standards were added (5pmol
Hexadecanoyl-L-carnitine chloride (71–1732-5 Larodan), 5 pmol
Octadecanoyl (18,18,18-D3)-L-carnitine chloride (71–1748 Larodan),
250 pmol Acetyl (D3)-L-carnitine chloride (71–1746-5 Larodan), 20
pmol Butyryl (4,4,4-D3)-carnitine chloride (71–1734 Larodan)). The
cell lysate was extracted in 3:1 ACN: MeOH, vortexed and spun down
for 10 min, 10.000 rpm, 4 °C. The sample was freeze-dried and re-
dissolved in 50 µl 0.1% formic acid. Sample (10 µl) was injected into
the HPLC-MS system. Samples were analysed on an Agilent 1290
HPLC coupled to an Agilent 6530 mass spectrometer. Analyte separa-
tion was achieved using a Agilent ZORBAX RRHD Eclipse Plus C18
column (2.1×150 mm2, 1.8 µm) with a Agilent ZORBAX Eclipse Plus
C18 guard column (2.1 mm, 1.8 µm) both heated to 40 °C, 300 µl/min
ﬂow of mobile phase 0.1% formic acid (A) and 0.1% formic acid in
acetonitrile (B) with the following gradient: 3% B for 5 min, to 15% B
over 3 min, to 30% B over 2 min, to 97% B over 9 min and 97% B for
3 min. Reference ions were infused with a ﬂow of 10 µl/min. The mass
spectrometer was operated in positive ion mode with the following
settings: 2 GHz extended dynamic range from 100 to 1500m/z, gas
temperature: 300 °C, drying gas ﬂow (nitrogen): 10 l/min, nebulizer:
35 psi, sheath gas temperature: 350 °C, Sheath gas ﬂow:11 L/min,
capillary voltage: 3500 V, fragmentor: 125 V, acquisition rate: 3
spectra/s, reference correction two points at m/z 121.050873 and m/
z 922.009798. MassHunter Proﬁnder, Agilent Technologies was used
to detect and quantify 14 diﬀerent acylcarnitine species. These were C0,
C2, C3, C4, C6, C8, C10, C12, C14, C16:1, C16, C18:2, C18:1, C18:0.
2.3. qPCR
Total RNA was puriﬁed and cDNA was synthesized as previously
described [9]. qPCR was performed on The LightCycler® 480 Real-
Time PCR system (Roche) using commercially available SYBR Green
Jumpstart Taq Ready Mix (Sigma) according to the manufacturer's
instructions. The following conditions were used: 2 min at 95 °C (hot
start), 40 cycles of 15 s at 95 °C, 45 s at 60 °C, and 45 s at 72 °C. The
CRAT expression was normalized against the expression of the house-
keeping gene TBP. The following primers were used: CRAT fwd: 5′-
GACACAGTCAGCAACTTCAGC, CRAT rev: 5′ GCTGCACAAA
GATCTGATCCG; TBP fwd: 5′-GCCCGAAACGCCGAATAT, TBP rev:
5′CCTCATGATTACCGCAGCAAA.
2.4. Western Blot
Proteins were extracted and analysed as previously described [9].
Protein concentration was determined using the Pierce BCA protein
assay kit and equal amounts of cell protein (10 μg) were loaded in each
well. Rabbit Anti-CRAT (1:250) (Sigma HPA022815) and Rabbit Anti-
VDAC1 (1:1000) were used as primary antibodies. VDAC1 was used as
loading control in order to normalize the protein abundance of CRAT
to the mitochondrial content. Horseradish peroxidase-conjugated goat
anti-rabbit IgG (1:2000) (Promega W401B) was used as secondary
antibody.
2.5. Statistics
Statistical analysis was calculated as One-way ANOVA with
Dunnett's multiple comparisons test using GraphPad Prism version
5.01. p < 0.05 was considered statistically signiﬁcant; n used for
analysis is the total number of individuals. Mean ± SEM is shown.
3. Results
The clinical characteristics show that fasting glucose, serum insulin
and HbA1c levels were signiﬁcantly higher, whereas the fasting HDL
cholesterol level was signiﬁcantly lower in T2DM patients compared to
lean controls, (Table 1). Serum insulin level was higher in obese
compared to lean controls, and the glucose infusion rate (GIR)
measured during the hyperinsulinemic euglycemic clamp was signiﬁ-
cantly lower in obese with and without T2DM compared to lean
controls (Table 1).
The protein and mRNA levels of CRAT were determined in cultured
myotubes from obese with and without T2DM and lean persons (Fig. 1
A and B). Our results show no signiﬁcant diﬀerence between the
investigated groups. By using LC-MS, no signiﬁcant diﬀerence was
found in the total acylcarnitine level (166.32 ± 8.37, lean; 170 ± 7.1,
obese; 130 ± 15.5, T2D, Mean ± SEM, pmol/mg protein, p < 0.05) (data
not shown) or among individual short- and medium-chain acylcarni-
tines between groups (Mean ± SEM, pmol/mg protein, and p < 0.05)
(Fig. 1C). Muscular levels of C16 and C18 carnitine (Mean ± SEM,
pmol/mg protein, p < 0.05) were signiﬁcantly reduced 36% and 53% in
T2DM patients compared to lean controls (Fig. 1C). No signiﬁcant
diﬀerences were observed among other long-chain acylcarnitines
(Mean ± SEM, pmol/mg protein, p > 0.05) (Fig. 1C).
Table 1
Clinical characteristics.
Control, lean Control, obese T2DM
N 9 9 9
Age (years) 50.8 ± 1 48.1 ± 1 50 ± 1
Weight (kg) 71.6 ± 3.0 105.5 ± 6.4* 102.2 ± 4.1*
BMI (kg/m2) 24.2 ± 0.5 34.0 ± 1.4* 33.5 ± 1.1*
Fasting plasma glucose
(mM)
5.7 ± 0.1 5.7 ± 0.2 10.0 ± 0.7#
Fasting serum insulin
(pM)
23.9 ± 5.7 52.6 ± 5.0* 96.7 ± 10.1#
Glucose infusion rate
(mg/min)
383.3 ± 20.4 254.1 ± 28.3* 117.8 ± 18.6#
HbA1c (%) 5.5 ± 0.1 5.4 ± 0.1 7.5 ± 0.5
#
Fasting total
cholesterol (mM)
5.29 ± 0.22 5.33 ± 0.41 5.42 ± 0.37
Fasting LDL cholesterol
(mM)
2.94 ± 0.22 3.18 ± 0.33 3.20 ± 0.27
Fasting HDL
cholesterol (mM)
1.85 ± 0.15 1.54 ± 0.15 1.36 ± 0.03*
Fasting plasma
triglyceride (mM)
1.12 ± 0.16 1.34 ± 0.18 1.93 ± 0.40
Data are means ± SEM.* Signiﬁcant diﬀerent from the lean controls (p < 0.05),#
signiﬁcant diﬀerent from the lean and obese controls (p < 0.05).
S.M. Berg et al. Biochemistry and Biophysics Reports 9 (2017) 47–50
48
4. Discussion
T2DM myotubes cultured under basal conditions express primary
insulin resistance and show several signs of impaired mitochondrial
function [6]. In the present study, we aimed to investigate to which
extent CRAT and acylcarnitine levels express alterations in myotubes
established from obese T2DM patients. The mRNA levels and protein
abundance of CRAT were similar between groups and C16- and C18-
carnitines were signiﬁcantly reduced in myotubes derived from T2DM
patients compared to glucose-tolerant obese and lean controls. These
data provide evidence that mRNA levels and proteins abundance of
CRAT are unaltered in T2DM muscle and does not result in accumula-
tion of acylcarnitine species. However, a reduction in C16 and C18
carnitine was seen, which suggests that CRAT is not important for
primary insulin resistance in T2DM muscle.
Our ﬁndings are in accordance with an early study with Zucker
diabetic fatty (ZDF) rats showing that the protein abundance of CRAT
was unchanged in ZDF rats on a normal diet, but lipid surplus inhibited
CRAT in order to counter-regulate glucose oxidation [3]. One could
speculate that CRAT activity is reduced despite that similar mRNA
expression and protein expression of CRAT are similar between groups.
Nevertheless, we did not see any signiﬁcant increase in the acetylcar-
nitine levels between groups, indicating that CRAT activity is unaltered.
Muoio and colleagues have shown that muscle-speciﬁc loss of
functional CRAT in mice could not regulate the ﬂux of acetyl CoA,
which resulted in accumulation of acetyl CoA within the mitochondria
and allosteric inhibition of pyruvate dehydrogenase (PDH), which
subsequently impaired glucose utilization [1]. Glucose intolerance,
insulin resistance, and metabolic inﬂexibility were seen in these mice
[1]. Interestingly, medium- and long-chain acylcarnitines accumulated
in muscle, which could suggest dysregulation in carnitine metabolism.
L-Carnitine supplementation for six month in transgenic mice with
muscle-speciﬁc loss of functional CRAT improved the insulin sensitiv-
ity suggesting that metabolic inﬂexibility was partially ameliorated by
carnitine supplementation [1]. In addition, previous studies have
shown that myotubes exposed to surplus of palmitate express second-
ary insulin resistance with concomitant increased acyl CoA levels [10],
and would expect that acylcarnitine will be increased based on mass
action. The exact mechanism for lipid-induced insulin resistance is
unknown, but both long-chain acyl-CoAs and acylcarnitines may be
part hereof giving the distinct functions of acylcarnitines in mitochon-
drial lipid metabolism such as preventing accumulation of noxious
long-chain acyl-CoAs and reducing CoA trapping. The increase in long-
chain acyl-CoA, diacylglycerol, and lipid oxidation products will
promote induction of insulin resistance though atypical protein kinase
C activation and decreases insulin stimulated activity of insulin
receptor substrate-1 associated phosphatidylinositol-3-kinase and sub-
sequently reduce glucose uptake and storage. Thus, CRAT may be an
important pathophysiological factor for the development of lipid-
induced insulin resistance, but not primary insulin resistance.
Further, studies have to clarify if CRAT activity is partly impaired by
lipids per se and thereby enhance acylcarnitine levels.
Fig. 1. CRAT expression and the acylcarnitine proﬁle in human myotubes. (A) The protein abundance of CRAT (70 kDa) was determined by western blotting using VDAC1 (31 kDa) as
loading control. Band intensities were quantiﬁed by densitometry and expressed as the ratio between CRAT and VDAC band intensities. (B) The mRNA level of CRAT was determined by
qPCR and normalized to TBP levels. (C) Acylcarnitine species in human myotubes obtained from obese persons with and without T2DM and lean controls were analysed by LC-MS.
Mean ± SEM is shown, n =9. Statistical analysis was assessed by One-way ANOVA with Dunnett's multiple comparisons test, *(p < 0.05).
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Taken together, the present study shows that CRAT and short-,
medium- or long-chain acylcarnitines are not important for primary
insulin resistance in myotubes derived from obese T2DM patients. The
precise events leading to primary insulin resistance in myotubes
derived from obese T2DM patients remain unanswered.
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